Our in-house capabilities: Research and development of finished dosage forms
The Powerhouse for the next generation of pharmaceuticals: Highest demands on formulations and innovation
Our in-house Research & Development forms the bedrock of our purpose to deliver better healthcare. Grow your brand with added value for patients through best-in-class formulations that meet the needs of their markets!
We see every development challenge as an opportunity to improve. The world´s most trusted brands count on our high excellence in pharmaceutical research and development, building the foundation for our broad and innovative product portfolio. Acting on the needs of our global customers for affordable high-quality medicines and the everchanging market, we target generics as well as value added and innovative pharmaceutical products. Whether it´s fewer side effects, a better API absorption or a personalized drug dispensing device, we believe that there are always new ways of smart medicines which better deliver on patients´ needs. We are in close and regular collaboration with universities and key opinion leaders of all relevant disciplines to develop pharmaceuticals more patient-centered than ever before.
Our own laboratories, the long-lasting experience of our scientists and our exclusive network of development partners enable us to cover all major indications as well as diverse and innovative dosage forms. We succeed in developing tablets, capsules, modified release formulations, oral and ophthalmic solutions as well as special technologies like patches, inhalers, injectables or personalized devices. Our current entire portfolio consists of 180 products: 100 dossiers, 40 products under development, and 40 in our pipeline. Committed to drive for growth and innovation part or our product range is a well-defined and specialized portfolio of highly potent drug formulations.
Outstanding intellectual property (IP) guidance and quality assurance (QA) are the backbone of our Research & Development operations to deliver better affordable high-quality pharmaceuticals worldwide.
Tiefenbacher research and development translates scientific progress into healthcare solutions
Your benefits of our advanced Research & Development operations
We, at TIEFENBACHER GROUP, constantly adapt and track the latest insights, to let our curiosity and science show us the way forward in healthcare.
Our research and development operations for better healthcare – by developing high-quality pharmaceuticals with added value for patients worldwide. We stand for reliability, the highest standards of safety and quality, and a forward-looking approach along the entire pharmaceutical value chain. Our capabilities span a wide range of development technologies – all backed by comprehensive industry knowledge and experience in drug development – including highly potent drugs.
150+
R&D Scientists
>
180+
FDF Products
>
Generics
cost-efficient drugs
>
Value added and innovation medicines
>
150+
R&D Scientists
>
180+
generic and innovative formulations
>
Generics
cost-efficient drugs
>
Value added and innovation medicines
>
Major indications and highly potent drugs
>
10+
Dosage forms
>
100%
FDA approved own laboratories
>
Quality Assurance and Intellectual Property
>
Major indications and highly potent drugs
>
10+
Dosage forms
>
100%
FDA approved
>
Quality Assurance and Intellectual Property
>
TIEFENBACHER Laboratories: drug development & manufacturing worldwide
With advanced technologies to pharmaceuticals of the future
Our state-of-the-art, FDA approved laboratories in India for drug development and commercialisation worldwide.
The research and development operations for both generic and innovative formulations are supported by our advanced laboratory in Hyderabad, India. TIEFENBACHER LABORATORIES features a GLP/GMP compliant environment on a 32.000 m² sized plant. Most modern techniques and softwares (e. g. inhouse XRD Crystallography, WinNonlin IVIVC simulation tools, Nitrosamine testing, Malvern particle size testing) are part of the state-of-the-art research & development equipment. With our new own high potent lab we are committed to drive for growth and innovation and are able to develop a well-defined and specialized portfolio of highly potent drug formulations inhouse. This includes the development of tablets as well as capsules.
Quality control is an integral part of TIEFENBACHER LABORATORIES. It ensures a development process which considers all aspects of quality and customer requirements, transparency, and applying good manufacturing practice (GMP) – according to national as well as international legislation. The development projects are performed following ICH, EU, USFDA and other international guidelines. This enables us to generate a corresponding documentation for the submission of a marketing authorization application in the EU, in the US, and further international territories. TIEFENBACHER LABORATORIES holds the ISO 14001:2014 and ISO 18001:2015 certifications and was successfully inspected by the German BGV, the US FDA authorities, the Russian MIT, and the Turkish Ministry of Health.
We are experts and innovators to improve people’s life
New Generation of pharmaceuticals: our new state-of-the-art lab for highly potent drugs
TIEFENBACHER GROUP is now able to develop and manufacture highly potent drugs in its new dedicated site in Hyderabad, India. These small molecules are so potent that they elicit therapeutic effects at lower doses. Our competence ranges from the first phase of research to the commercial production of drugs for the treatment of cancer and other conditions – for both tablets and capsules. The new state-of-the-art lab is equipped with the most modern techniques and software and will be supplemented by a new manufacturing block with special technologies in 2023. The whole complex will cover a total of about 4.000 square meters.
TIEFENBACHER PHARMACEUTICALS (FDF business unit of TIEFENBACHER GROUP) has already 25 leading highly potent drugs in its launch pipeline which are planned to be developed and produced in-house in the new facilities in Hyderabad for a market entry around the globe. While the operational start of the lab has already started (including small-scale production), the commercial production for larger quantities in the new manufacturing block is expected for 2024.
For more information about our highly potent competence and innovative technologies, please contact us at any stage of your inquiry – by filling out the contact form below on this webpage, or please directly send an email to info@aet.eu
TIEFENBACHER GROUP: We use innovative science and technology to improve people’s lives.
Do not hesitate to get in touch for more information about our research & development solutions for better affordable high-quality pharmaceuticals worldwide. Our experts are always available to help – from the idea through drug development to commercialization for patients worldwide.
For more information about our better healthcare – generics, value added, and innovative products – please contact us by filling out the contact form below and clicking “Send message”, or please directly send an email to info@tiefenbacher.com. TIEFENBACHER GROUP will follow up with you personally as soon as possible.
